Tatva Chintan Pharma Chem Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Tatva Chintan Pharma Chem (NSE: TATVA) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock trading at Rs 1,250 — against a 52-week high of Rs 1,800 and a 1-year return of -28% — the Q4 FY26 results will be a pivotal event for investors.

Analyst estimates for Q4 FY26 revenue stand at Rs 240-265 Cr, with PAT expectations of Rs 32-42 Cr and margin projections of EBITDA 22-25%. This article covers the Tatva Chintan Pharma Chem Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and the most commonly searched investor questions.

Tatva Chintan Pharma Chem Q4 Results 2026 Date

Get free investment predictions and live Q4 result alerts on Univest.

Tatva Chintan Pharma Chem has scheduled its Q4 FY26 results for May 2026 (Expected). Here is the broader Q4 FY26 earnings calendar:

Why This Quarter Matters

Tatva Chintan Pharma Chem enters Q4 FY26 with expectations of 12-16% YoY revenue growth. Q4 is the final quarter of FY26 — it determines full-year performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -28%, this quarter’s results and FY27 guidance will be critical in determining whether the stock can sustain recovery momentum.

Tatva Chintan Pharma Chem Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

A positive surprise on any two of the four key parameters — revenue, margin, guidance, and dividend — could drive a meaningful post-results re-rating.

Screen Tatva Chintan Pharma Chem fundamentals on Univest Screener.

5 Key Factors That Will Drive Tatva Chintan Pharma Chem Q4 FY26 Performance

Revenue Momentum

Analysts expect Rs 240-265 Cr in Q4 FY26 revenue versus Rs 214 Cr in Q3. Q4 is seasonally important for the Chemicals/Specialty sector. The ability to convert the pipeline into recognised revenue will be the first performance test investors focus on when results are declared.

Margin Trajectory

Q4 FY26 margin expectations are EBITDA 22-25% versus EBITDA 22.4% in Q3. Input cost trends, employee expenses, and pricing power will determine whether the company can sustain or improve on Q3 levels. Any margin beat would be a significant positive catalyst for the stock.

PAT Quality

Net profit is estimated at Rs 32-42 Cr. Investors will closely assess whether PAT is driven by operational improvement or non-recurring items. A clean, recurring profit print is most positively received by institutional investors tracking the stock.

Management Guidance for FY27

The most consequential output will be FY27 guidance — revenue growth bands, margin targets, and capex plans. In the current global macro environment, credible and specific FY27 guidance will be valued more than usual by the market.

Dividend Declaration

Tatva Chintan Pharma Chem is expected to consider a final dividend of Rs 4-6 per share. The quantum signals management’s confidence in free cash flow generation and sets expectations for FY27 capital allocation strategy.

5 Risks to Watch in Tatva Chintan Pharma Chem Q4 FY26

US Tariff and Macro Headwinds

The 26% US reciprocal tariff on Indian goods has created macro uncertainty across all Indian equities. For Tatva Chintan Pharma Chem, indirect impacts include FII outflows and potential earnings estimate cuts if global demand slows. Progress in India-US trade negotiations remains the most important macro catalyst.

Earnings Miss Risk

If Tatva Chintan Pharma Chem’s Q4 FY26 results miss estimates, the stock could correct sharply regardless of longer-term fundamentals. Investors should monitor revenue versus the Rs 240-265 Cr estimate and PAT versus Rs 32-42 Cr as the two primary watchpoints.

FY27 Guidance Below Consensus

If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. In the current environment, forward guidance carries more weight than the reported quarter.

FII Outflow Continuation

FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling pressure would create headwinds for Tatva Chintan Pharma Chem regardless of company-specific fundamentals.

Sector Regulatory Risk

The Chemicals/Specialty sector faces evolving regulatory frameworks. Any policy changes that increase compliance costs or alter competitive dynamics could affect Tatva Chintan Pharma Chem’s profitability beyond current consensus models.

Tatva Chintan Pharma Chem Share Price and Analyst Ratings

Tatva Chintan Pharma Chem is trading at Rs 1,250 as of early April 2026, against a 52-week high of Rs 1,800 and a 52-week low of Rs 940. Market cap stands at Rs 3,100 Cr. The 1-year return of -28% reflects sector headwinds alongside company-specific factors.

Download the Univest iOS App or Univest Android App to track Tatva Chintan Pharma Chem’s live price and receive real-time Q4 result alerts.

Conclusion

Tatva Chintan Pharma Chem Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Chemicals/Specialty sector. Analysts project PAT of Rs 32-42 Cr and revenue of Rs 240-265 Cr. At a CMP of Rs 1,250 and analyst targets ranging from Rs 1,550 to Rs 1,650, the stock offers meaningful risk-reward for informed investors. FY27 guidance will be the most critical post-results catalyst.

For more Q4 FY26 previews across sectors, visit Univest Blogs.

Frequently Asked Questions

What is the Tatva Chintan Pharma Chem Q4 results 2026 date?

The Tatva Chintan Pharma Chem Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a dividend recommendation for FY26.

What is the Tatva Chintan Pharma Chem Q4 FY26 PAT estimate?

Analysts estimate Tatva Chintan Pharma Chem Q4 FY26 PAT at Rs 32-42 Cr, based on revenue of Rs 240-265 Cr and margin of EBITDA 22-25%. Actual results may differ from consensus estimates.

What is Tatva Chintan Pharma Chem’s share price ahead of Q4 results?

Tatva Chintan Pharma Chem is trading at Rs 1,250. The 52-week high is Rs 1,800 and low is Rs 940. The 1-year return is -28% and market cap is Rs 3,100 Cr.

Will Tatva Chintan Pharma Chem declare a dividend in Q4 FY26?

Tatva Chintan Pharma Chem is expected to consider a final dividend of Rs 4-6 per share at the Q4 FY26 board meeting on May 2026 (Expected).

Which analysts have a Buy rating on Tatva Chintan Pharma Chem?

MOFSL (Buy, Rs 1,650), YES Securities (Buy, Rs 1,600), JM Financial (Add, Rs 1,520), Emkay (Buy, Rs 1,550) have positive ratings heading into Q4 FY26.

What were Tatva Chintan Pharma Chem Q3 FY26 results?

Tatva Chintan Pharma Chem reported Q3 FY26 revenue of Rs 214 Cr and PAT of Rs 28 Cr, with margin at EBITDA 22.4%. These form the baseline for Q4 FY26 consensus estimates.

When do Infosys and TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview on Univest Blogs. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read the Infosys Q4 Results 2026 preview on Univest Blogs.

Is Tatva Chintan Pharma Chem a good investment ahead of Q4 results?

This depends on your risk appetite and portfolio context. Tatva Chintan Pharma Chem has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before making any investment decision.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Recent Article

TCS Share Price Target 2026 — Key Factors, Financial Performance & Analyst Forecast

Nestle India Share Price Target 2026 — Key Factors, Financial Performance & Analyst Forecast

State Bank of India Share Price Target 2026: Analyst Forecasts, Bull & Bear Case

Hindustan Unilever Share Price Target 2026 — Key Factors, Financial Performance & Analyst Forecast